Article Test

Abstract

Choosing an agent for initial or add-on therapy in type 2 diabetes can be overwhelming for clinicians due to the numerous agents available.  Patient specific characteristics, such as the presence of obesity or renal complications, further complicate treatment choices.  In clinical studies, albiglutide has been compared to placebo, oral diabetes medications, as well as other injectable agents.  The most common adverse effects associated with albiglutide are gastrointestinal in nature, an adverse effect which often subsides with continued use.  Serious adverse effects, as with all GLP-1RAs, warrant cautious use of albiglutide in certain patient populations.  In addition to its proven safety and efficacy profile, albiglutide may afford patients the added benefits of potential weight loss and improved adherence.